Sunesis Pharmaceuticals Announces Presentations at ASH Annual Meeting
04 November 2016 - 12:25AM
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced an oral
and a poster presentation at the 58th American Society of
Hematology Annual Meeting to be held December
3-6 in San Diego, California.
The details for the oral presentation are as follows:
Date and Time: Monday,
December 5, 2016 at 3:15 p.m. Pacific Time
Abstract Title: Durable
Overall Survival Benefit in Patients ≥ 60 Years with Relapsed or
Refractory AML Treated with Vosaroxin/Cytarabine Vs
Placebo/Cytarabine: Updated Results from the Valor
TrialSession Number: 616
Session Name: Acute Myeloid
Leukemia: Novel Therapy, excluding Transplantation: Clinical trials
of Novel Drugs and Combinations in AMLPublication
Number: 903
Location: Marriott Marquis
San Diego Marina, San Diego Ballroom AB
The full abstract can be viewed here.
The details for the poster presentations are as follows:
Date and Time: Saturday,
December 3, 2016, 5:30 PM-7:30 PM Abstract
Title: First-in-Human Phase 1a Study
of the Safety, Pharmacokinetics, and Pharmacodynamics of the
Noncovalent Bruton Tyrosine Kinase (BTK) Inhibitor SNS-062 in
Healthy Subjects Session Number:
642Session Name: CLL:
Therapy, excluding Transplantation: Poster I Publication
Number: 2032
Location: San Diego
Convention Center, Hall GH
The full abstract can be viewed here.
About Sunesis
Pharmaceuticals
Sunesis is a biopharmaceutical company focused
on the development and commercialization of new oncology
therapeutics for the potential treatment of solid and hematologic
cancers. Sunesis has built a highly experienced cancer drug
development organization committed to improving the lives of people
with cancer. Currently, the company is focused on pursuing
regulatory approval in Europe for its lead product candidate,
vosaroxin, for the treatment of relapsed or refractory acute
myeloid leukemia in patients aged 60 and older, as well as
advancing its novel kinase-inhibitor pipeline, which includes its
proprietary non-covalent BTK-inhibitor, SNS-062.
For additional information on Sunesis, please
visit http://www.sunesis.com.
SUNESIS and the logos are trademarks
of Sunesis Pharmaceuticals, Inc.
This press release contains forward-looking
statements, including statements related to Sunesis' corporate
objectives, including the regulatory development and potential
approval of vosaroxin by the EMA, potential collaborations and
ability to commercialize vosaroxin in Europe. Words such as
“expect,” “goal,” “may,” "potential" “advancing,” “anticipate,”
“progress” and similar expressions are intended to identify
forward-looking statements. These forward-looking statements are
based upon Sunesis' current expectations. Forward-looking
statements involve risks and uncertainties. Sunesis' actual results
and the timing of events could differ materially from those
anticipated in such forward-looking statements as a result of these
risks and uncertainties, which include, without limitation, the
risk that Sunesis may not be able to receive regulatory approval of
vosaroxin in the U.S. or Europe, that Sunesis' development
activities for vosaroxin could be otherwise halted or significantly
delayed for various reasons, risks related to Sunesis' need for
substantial additional funding to complete the development and
commercialization of vosaroxin and other product candidates, the
risk that Sunesis' clinical studies for SNS-062, vosaroxin or other
product candidates, including its pipeline of kinase inhibitors,
may not demonstrate safety or efficacy or lead to regulatory
approval, the risk that data to date and trends may not be
predictive of future data or results, risks related to the conduct
of Sunesis' clinical trials, and risks related to Sunesis' ability
to raise the capital that it believes to be accessible and is
required to fully finance the development and commercialization of
vosaroxin and other product candidates. These and other risk
factors are discussed under "Risk Factors" and elsewhere in
Sunesis' Annual Report on Form 10-K for the year
ended December 31, 2015, Sunesis’ Quarterly Report on Form
10-Q for the quarter ended September 30, 2016, and Sunesis' other
filings with the Securities and Exchange Commission.
Sunesis expressly disclaims any obligation or undertaking to
release publicly any updates or revisions to any forward-looking
statements contained herein to reflect any change in Sunesis'
expectations with regard thereto or any change in events,
conditions or circumstances on which any such statements are
based.
Investor and Media Inquiries:
David Pitts
Argot Partners
212-600-1902
Eric Bjerkholt
Sunesis Pharmaceuticals Inc.
650-266-3717
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Sep 2024 to Oct 2024
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Oct 2023 to Oct 2024